|
|
Article: Guidelines for the Optimal Use of Muromonab CD3 in Transplantation.
- Article from:
- Immunotherapy Weekly
- Article date:
- May 24, 1999
CopyrightCOPYRIGHT 1999 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Monoclonal Antibodies
Tenberge, I.J.M.; Parlevliet, K.J.; Raasveld, M.H.M.; Buysmann, S.; Bemelman, F.J.; Schellekens, P.T.A. "Guidelines for the Optimal Use of Muromonab CD3 in Transplantation." Biodrugs, April 1999;11(4):277-284.
(CW HENDERSON PUBLISHER www.newsfile.com) -- According to the authors' abstract of an article published in Biodrugs, "Muromonab CD3 (OKT3), the murine anti-CD3 monoclonal antibody (mAb) of the IgG-2a class, directed against the CD3 molecule on the surface of human T cells, has proven to be a powerful immunosuppressive agent in solid organ transplantation and has been shown to be superior to high-dose steroids as first-line ...